Only a few of the more than 3,000 radioisotopes that scientists have synthesized in the laboratory are regularly used in diagnostic or therapeutic medicine. One significant barrier to the development of new medical radioisotopes is the difficulty of gaining access to radionuclides during the early stages of development and research. PRISMAP is a new medical radionuclide program designed to streamline that access for medical research in the European Union and the United Kingdom.